Panobinostat (LBH589)

Catalog No.S1030 Synonyms: NVP-LBH589

Panobinostat (LBH589) Chemical Structure

Molecular Weight(MW): 349.43

Panobinostat (LBH589) is a novel broad-spectrum HDAC inhibitor with IC50 of 5 nM in a cell-free assay. Phase 3.

Size Price Stock Quantity  
USD 90 In stock
USD 270 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 48 Publications

12 Customer Reviews

  • (G) A375 parental and BRAFi-resistant ex vivo clones were treated with a panel of HDACi (1 μM vorinostat, 0.5 μM belinostat, and 6 nM panobinostat) in single treatment or in combination with 1 μM vemurafenib in a long-term colony formation assay.

    Cell, 2018, 173(6):1413-1425. Panobinostat (LBH589) purchased from Selleck.

    LSD1 and HDAC inhibitors exhibit synergistic growth inhibition. Cells were simultaneously treated with pargyline or HDAC inhibitors for 48 h.

     

     

    Breast Cancer Res Treat 2012 131, 777-789. Panobinostat (LBH589) purchased from Selleck.

  • Using CRISPR-Cas9 technology, ERα was silenced at the genomic level in ECC1 cells. Ishikawa, parental ECC1 cells and individual ESR1 KO ECC1 clones were treated with 20 nM LBH589 for 24 hr. Expression of ERα, PR, FOXO1, and Myc were evaluated by Western blotting. β-actin serves as a loading control.

    PLoS One, 2016, 11(2):e0148912.. Panobinostat (LBH589) purchased from Selleck.

    HDACIs That Simultaneously Inhibit HDACs 1 and 6 Showed Greater Antileukemic Activities than HDACIs that Don’t at Cmax Concentrations. THP-1 cells were treated with LBH-589, PXD101, SAHA, VPA, MS-275 and MGCD0103 at Cmax concentrations for 3 h and 24 h, respectively. The cells post 3 h treatments were washed three times with complete medium and divided into two halves. One half of the cells was resuspended in complete media and cultured for up to 24 h to determine the effects of the 3 h treatments on cell proliferation and apoptosis. The other half of the cells was used to prepare whole cell lysates. Whole cell lysates from the 3 h and 24 h treatments were extracted and subjected to Western blots probed by anti-ac-tubulin or –b-actin antibody (panels A&B), or subjected to HDAC1 enzymatic assays post IP as described in the Materials and Methods (Panels C&D). The effects of the 3 h and 24 h HDACI treatments on cell proliferation, as reflected by percent decrease of live cells relative to untreated cells (panel E), and apoptosis (panel F) were determined by flow cytometry analysis as described in the Materials and Methods.

     

     

    PLoS One 2011 6, e17138. Panobinostat (LBH589) purchased from Selleck.

  • Induction of DNA Damage and Bim Is Critical for HDACI-Induced Apoptosis in Pediatric AML Cells. THP-1 cells were treated with the HDACIs at Cmax concentrations for 3 (panel A) and 24 h (panel B), respectively. Whole cell lysates were extracted and subjected to Western blots probed by anti-p21, -c-Myc, -cH2AX, -Bim, or -b-actin antibody.

     

     

    PLoS One 2011 6, e17138. Panobinostat (LBH589) purchased from Selleck.

    Cell death induction by LBH589 as a single agent was detected in control or MTDH knockdown Hec50co cells. After 3 days, cell death was determined by the WST-1 method.

    PLoS One 2011 6, e20920. Panobinostat (LBH589) purchased from Selleck.

  • Expression of pro-/anti-apoptosis genes. Control or MTDH knockdown Hec50co cells were treated for 24 hours with vehicle control, 20 nM LBH589, 25 ng/ml TRAIL or LBH589 and TRAIL at the concentrations noted. Lysates were collected. Expression of DR4, DR5, and apoptosis related caspase-3, caspase-8, PARP-1, BID, FLIP, XIAP, Bim, MCL-1 and BCL-XL was analyzed by Western blotting.

    PLoS One 2011 6, e20920. Panobinostat (LBH589) purchased from Selleck.

    p53(+/+) and (/) HCT116 cells were treated with TSA (1–5 lM),LBH589 (2–5 lM), valproate (2.5–5 mM), MS-275 (20 lM) and sodium butyrate (2 mM). TAp63 expression was compared in both cell lines after 24 h of treatment. Consistent with the above data, all HDAC inhibitors failed to induce significant levels of TAp63 in p53(/) HCT116 cells.

     

     

    Biochem Bioph Res Co 2009 391, 1748-1751. Panobinostat (LBH589) purchased from Selleck.

  • Effect of panobinostat on the viability of cervical cancer cells. HeLa (A) and SiHa (B) cells were treated with increasing concentrations of panobinostat for 24, 48 and 72 h. Cell viability was determined by MTT assay. The results are presented as percentage; calculated from the reduction in cell viability at a given concentration of drug compared to the untreated control (untreated control being 100%). The IC5072h values were calculated from sigmoidal dose-response curves generated in Prism 5.0 (GraphPad). (C) Cytotoxic effects of panobinostat on HeLa and SiHa cells measured at 72 h and expressed as% cell death. Each value is the mean ± SD of three independent experiments performed in triplicates.

    Biomed Pharmacother, 2016, 84:1393-1405. Panobinostat (LBH589) purchased from Selleck.

    Western blot analysis of Acetyl-H3 and H3. 0-10μM Panobinostat was added.

    Dr.Zhang of Tianjin Medical University. Panobinostat (LBH589) purchased from Selleck.

  • HDAC inhibitors induce p63a expression (A) HCT116 cells were treated with TSA (1 lM), LBH589 (2 lM), valproate (2.5 mM), MS-275 (20 lM) and sodium butyrate(2 mM) for 24 h. Expression of p63 was assessed by Western blotting with the H129 pan-anti-p63 antibody. Although TSA and LBH589 induced p63 efficiently, valproate, MS-275 and sodium butyrate were much less efficient. The lower panel shows the actin loading control. Arrow indicates TAp63. (B) The HDAC inhibitors used in this study are shown, grouped according to their structure and with their HDAC specificity. The efficiency of TAp63 expression is shown in the last column.

     

     

    Dr. Berna S. Sayan of Leicester University. Panobinostat (LBH589) purchased from Selleck.

    U266 and KMS-11 were treated with 20 nM panobinostat for 48 h followed by Western blot analysis. Actin served as a loading control. Nine (U266) and 3 (KMS-11) biologically independent experiments were performed. To determine the expression of PPP3CA mRNA in treated cells for 24 h, we performed relative quantification real-time PCR (n = 6). Four (U266) and 2 (KMS-11) biologically independent experiments were performed.

    JCI Insight, 2016, 1(5):e85061. Panobinostat (LBH589) purchased from Selleck.

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description Panobinostat (LBH589) is a novel broad-spectrum HDAC inhibitor with IC50 of 5 nM in a cell-free assay. Phase 3.
Targets
HDAC (MOLT-4 cells) [1] HDAC (Reh cells) [1]
5 nM 20 nM
In vitro

LBH589 induces apoptosis among MOLT-4 and Reh cells in a time- and dose-dependent manner. Moreover, LBH589 is more potent in MOLT-4 than in Reh cells. LBH589 markedly prevents the growth of both MOLT-4 and Reh cells in a dose-dependent manner at 48 hours. LBH589 treatment causes a 2- to 3-fold increase in the number of cells in the G2/M phase of the cell cycle compared with the control cells. LBH589 is associated with induction of histone H3K9 and histone H4K8 acetylation as well as decreasing levels of c-Myc expression in a dose-dependent manner. LBH589 treatment also increases the levels of p21 expression. LBH589 treatment also decreases the levels of c-Myc after an initial increase at the lowest dose (10 nM) in Reh cells. In addition, LBH589 gives rise to substantial increases in mRNA levels of proapoptosis and DNA repair genes. LBH589 induces increased levels of acetylated histone H3 and H4 at the GADD45G promoter. [1] Besides, LBH589 inhibits growth of non small cell lung cancer cell lines (such as human H1299, L55 and A549 with IC50 of 5 nM, 11 nM and 30 nM, respectively), mesothelioma (such as human OK-6 and Ok-5 with IC50 of 5 nM and 7 nM, respectively) and small cell lung cancer cell lines (such as human RG-1 and LD-T with IC50 of 4 nM and 5 nM, respectively). [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HT29 M2jZS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{jR[FAuOTBizszN MV2wMVQh\A>? NH6yVINqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMYRmeGWwZHXueEBu[W6wZYK= M1TNeFI3PzB{N{i0
HepG2 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3LXdFAuOTBizszN NHX5R4MxNTRiZB?= NX7qVXV{cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lMUBidmRiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NWf6VHpVOjZ5MEK3PFQ>
HT29 MnGySpVv[3Srb36gRZN{[Xl? NH\LO5U2OMLibl2= MomyNlQuPzJiaB?= MXfpcoR2[2WmIHHjeIl3[XSrb36gc4Yh[2G|cHHz[UA{KGGodHXyJFQ5yqCqwrC= Mo\VNlY4ODJ5OES=
HepG2 M4nKSmZ2dmO2aX;uJGF{e2G7 NGj6S|A2OMLibl2= NHWyfnYzPC15MjDo NYnBUlI{cW6mdXPl[EBi[3SrdnH0bY9vKG:oIHPhd5Bie2ViMzDh[pRmeiB{NNMgbOKh M1foflI3PzB{N{i0
HCC827 NVTvNHQ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUnyV4JIPS95LkWvNVAhdk1? NYHSSFdCPzMEoHi= MVHEUXNQ NYGzfpM2\W6qYX7j[ZMhfGinIHHueIlxem:uaX\ldoF1cX[nIHXm[oVkfCCxZjDldoxwfGmwaXK= MlnnNlY3PzV2OES=
A549  MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVuxNE8yPS9{MDDuUS=> NHLhSpI4OsLiaB?= MljCSG1UVw>? MWrlcohidmOnczD0bIUh[W62aYDyc4xq\mW{YYTpeoUh\W[oZXP0JI9nKGW{bH;0bY5q[g>? Ml;CNlY3PzV2OES=
NCI-H460  Mny0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnzKNVAwOjBxM{Cgcm0> MXK3NuKhcA>? MoS3SG1UVw>? M1nV[oVvcGGwY3XzJJRp\SCjboTpdJJwdGmoZYLheIl3\SCnZn\lZ5Qhd2ZiZYLsc5Rqdmmk NFTu[40zPjZ5NUS4OC=>
J89GFP NWjmfpZGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;IXWROW00EoB?= NG\kW41GSzVyPUS5Mlg2KMLzIEGyMlY2KG6P MljMNlY2PjN3Nki=
THP89GFP NFHrOnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlLrSG1UV8Li MX7FR|UxRTF7LkO0JOKyKDZwNEOgcm0> NFzjfmYzPjV4M{W2PC=>
SK-NEP-1 M4PqVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlvwNE4xOeLCk{GwMlAh|ryP MlmxNlQhcA>? M37oNGROW00EoB?= M3nmOGlEPTB;N{[uN|Qhdk1? NUjQWllJOjZzN{[yNVk>
G401 NUXnRmo4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYjHPXg5OC5yMfMAl|ExNjBizszN NH;YeW8zPCCq NH;LVWFFVVORwrC= NIjwbWdKSzVyPUG0N{4xOiCwTR?= NFfC[GMzPjF5NkKxPS=>
SK-NEP-1 NVy2VHVMS2WubDDWbYFjcWyrdImgRZN{[Xl? M2XUNVUxKG6P M1nUV|HjiJN2IHS= NVX0eIFwTE2VT9Mg NH;3[mdz\WS3Y3XzJINmdGxic4Xyeol3[WxiaX6gZUB1cW2nIHTldIVv\GWwdDDtZY5v\XJ? M4m0cVI3OTd4MkG5
G401 MmfKR4VtdCCYaXHibYxqfHliQYPzZZk> Mm\NOVAhdk1? M2jpVVHjiJN2IHS= NHW5TIhFVVORwrC= M3fSb5Jm\HWlZYOgZ4VtdCC|dYL2bZZidCCrbjDhJJRqdWViZHXw[Y5l\W62IH3hco5meg>? M{\lNlI3OTd4MkG5
SK-NEP-1 NF3wVppCeG:ydH;zbZMhSXO|YYm= NWjVdY1bPTBxMUCwJI5O MUGyOEBp MYDEUXNQyqB? MVHpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NHG1W3YzPjF5NkKxPS=>
G401 NE\RNpFCeG:ydH;zbZMhSXO|YYm= MkDOOVAwOTByIH7N MXuyOEBp M3;KNGROW00EoB?= MlnMbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M3LIOFI3OTd4MkG5
SK-NEP-1 NXixNZpXTnWwY4Tpc44hSXO|YYm= MY[1NE8yODBibl2= NInmVlQzPCCq M17B[2ROW00EoB?= M3Lnb5Npd3e|IITo[UBqdmS3Y4Tpc44hd2ZiRF7BJIZz[WevZX70ZZRqd25? NF\wXHIzPjF5NkKxPS=>
G401 MX7GeY5kfGmxbjDBd5NigQ>? MW[1NE8yODBibl2= Ml7sNlQhcA>? Mli3SG1UV8Li NUjxeXBxe2ixd4OgeIhmKGmwZIXjeIlwdiCxZjDEUmEh\nKjZ33lcpRifGmxbh?= Mn24NlYyPzZ{MUm=
SK-NEP-1 M{L5[GZ2dmO2aX;uJGF{e2G7 NX\mOZg6PTBxMUCwJI5O MnTYNlQhcA>? NEPDNmNFVVORwrC= M3iwRYlv\HWlZYOgZ4VtdCCleXPs[UBlcXOxcnTlduKh M4LnZVI3OTd4MkG5
G401 NGDpSnVHfW6ldHnvckBCe3OjeR?= M1LlRVUxNzFyMDDuUS=> M1XsclI1KGh? NGTEcoRFVVORwrC= MlfYbY5lfWOnczDj[YxtKGO7Y3zlJIRqe2:{ZHXyxsA> M2TuW|I3OTd4MkG5
RPMI 8226 NVH0bY9oS2WubDDTeZJ3cX[jbDDBd5NigQ>? MkLjNk81NzZibl2= NXjPW2VrPDkkgJno MnPKbY5lfWOnczDhJJNq\26rZnnjZY51KGSnY4LlZZNmKGmwIITo[UBk\WyuIHfyc5d1cA>? MWWyOlAxODJ7Mh?=
OPM2 NGTuVHZE\WyuIGP1dpZqfmGuIFHzd4F6 NVP3V5BROi92L{[gcm0> M1TFV|Q56oDLaB?= MkHhbY5lfWOnczDhJJNq\26rZnnjZY51KGSnY4LlZZNmKGmwIITo[UBk\WyuIHfyc5d1cA>? NEPBeFYzPjByMEK5Ni=>
U266 NU[2dldGS2WubDDTeZJ3cX[jbDDBd5NigQ>? MUeyM|QwPiCwTR?= Mon5OFjjiImq MVjpcoR2[2W|IHGgd4lodmmoaXPhcpQh\GWlcnXhd4UhcW5idHjlJINmdGxiZ4Lve5Rp MXqyOlAxODJ7Mh?=
H929 NXnnfJpUS2WubDDTeZJ3cX[jbDDBd5NigQ>? MWqyM|QwPiCwTR?= NUCzZ3hkPDkkgJno NYi3ZZNFcW6mdXPld{BiKHOrZ37p[olk[W62IHTlZ5Jm[XOnIHnuJJRp\SClZXzsJIdzd3e2aB?= NFGxUJczPjByMEK5Ni=>
RPMI 8226  NHTuWXpCeG:ydH;zbZMhSXO|YYm= Ml;WOQKBkW6P MkTzNlQwPDhiaB?= MUjpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHGgeIlu\S2mZYDlcoRmdnRibXHucoVz NHvycGEzPjByMEK5Ni=>
HCC827 MmPaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFzDb2syOCCwTR?= NVe3XXZwPDhiaB?= MnPGSG1UVw>? NWHYfmU1\W6qYX7j[ZMh[2m|cHzheIlvKHOnboPpeIl3cXS7wrC= MYiyOVk1PDZzNx?=
NCI-H23 NUmzN5k1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXrYZnQ1OTBibl2= MmDPOFghcA>? MlrsSG1UVw>? Mmr3[Y5p[W6lZYOgZ4l{eGyjdHnuJJNmdnOrdHn2bZR6yqB? NFHyPIwzPTl2NE[xOy=>
AML3 MVjGeY5kfGmxbjDBd5NigQ>? NVnRUpU6OC1zIN88US=> NXXkb29[OjUEoHi= M4HlNolv\HWlZYOgSG5CKG[{YXft[Y51[XSrb39CpIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NXzVdFFLOjV4MUK5OFE>
ML-1 NX;JUXFVTnWwY4Tpc44hSXO|YYm= MUmwMVEh|ryP MX6yOOKhcA>? MY\pcoR2[2W|IFTORUBnemGpbXXueIF1cW:wwrDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= M4GwbVI2PjF{OUSx
RPMI-8226vr10  NHq4dohHfW6ldHnvckBCe3OjeR?= M1r0SVAuOSEQvF2= NYj5UGh3OjUEoHi= MUXpcoR2[2W|IFTORUBnemGpbXXueIF1cW:wwrDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NWWxO3BNOjV4MUK5OFE>
ML-1 MXLGeY5kfGmxbjDBd5NigQ>? NVf1SVFtOSEQvF2= NHjQUVQzPMLiaB?= MnTIbY5kemWjc3XzJINie3Cjc3WtN{Bi[3Srdnn0fUA1NW[xbHS= MX6yOVYyOjl2MR?=
RPMI-8226vr10  NWLFUY8xTnWwY4Tpc44hSXO|YYm= MUCxJO69VQ>? Ml;RNlTDqGh? NGPuXFJqdmO{ZXHz[ZMh[2G|cHHz[U0{KGGldHn2bZR6KDJwNT3mc4xl M1X1e|I2PjF{OUSx
SK-N-BE (2) MlTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjET2YzPOLCiXi= MXfJR|UxRTFyND6w5qCKyrIkgJm3Mlghdk1? MmPONlU{ODh7MU[=
SK-N-BE (2), PAN  MK MmrBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYP4UI1{OjUkgJno NFjW[HFKSzVyPUGwOE4x6oDLwsJihKk4Njhibl2= MVeyOVMxQDlzNh?=
SK-N-BE (2), MK  PAN NWH6bGVvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXfibWZWOjUkgJno MlOwTWM2OD1|OEKuNQKBkcLz4pEJOFMvOiCwTR?= MWmyOVMxQDlzNh?=
SK-N-AS NUO1N3RoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXGyOQKBkWh? MnjMTWM2OD1|Nz6x5qCKyrIkgJmyMlQhdk1? NWr4eI1nOjV|MEi5NVY>
SK-N-DZ NYDRe5ZiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWeyOQKBkWh? M1jTdmlEPTB;MUeuNgKBkcLz4pEJNE41KG6P NXnFUolKOjV|MEi5NVY>
Caki-1 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\UcJoyOC9{NT:1NEBvVQ>? MUm0PEBp NWHFemJGcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJic4nu[ZJocXO2aXPhcIx6KHerdHigdol1d26jdnny NEfyV4szPTJ5OUG5NS=>
ACHN M3XTeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\QVFBWOTBxMkWvOVAhdk1? MXe0PEBp M2ft[YlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVzKHO7bnXy[4l{fGmlYXzsfUB4cXSqIILpeI9v[X[rch?= NVn2fHpoOjV{N{mxPVE>
769-P MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV6xSYtJOTBxMkWvOVAhdk1? MlvVOFghcA>? MmT0bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZIhe3mwZYLnbZN1cWOjbHz5JJdqfGhicnn0c45ifmm{ Mn[1NlUzPzlzOUG=
786-O  NFvWc4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnO1NVAwOjVxNUCgcm0> NITOVJU1QCCq NFTpT25qdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meiC|eX7ldodqe3SrY3HscJkhf2m2aDDybZRwdmG4aYK= MkLNNlUzPzlzOUG=
Caki-1 MlPKRZBweHSxc3nzJGF{e2G7 MY[1NEBvVQ>? M3T5NlQ5KGh? MmX2bY5lfWOnczDj[YxtKGGyb4D0c5NqeyClb33ibY5m\CC{aYTvcoF3cXJ? M3LYOlI2Ojd7MUmx
ACHN M4\ySmFxd3C2b4Ppd{BCe3OjeR?= MWC1NEBvVQ>? MnrhOFghcA>? MnnUbY5lfWOnczDj[YxtKGGyb4D0c5NqeyClb33ibY5m\CC{aYTvcoF3cXJ? NILJSpAzPTJ5OUG5NS=>
769-P NFf5WWpCeG:ydH;zbZMhSXO|YYm= NXr2RpdXPTBibl2= M2XYUFQ5KGh? NVjERolZcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDjc41jcW6nZDDybZRwdmG4aYK= MnPuNlUzPzlzOUG=
786-O  MoWyRZBweHSxc3nzJGF{e2G7 MUO1NEBvVQ>? NFfYXpc1QCCq MkTubY5lfWOnczDj[YxtKGGyb4D0c5NqeyClb33ibY5m\CC{aYTvcoF3cXJ? Mn7sNlUzPzlzOUG=
Caki-1 M1HKemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHPlPVIzPS93MDDuUS=> NYOwOGlWPDhiaB?= NWfDe3dLTE2VTx?= M{DLXolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVzKHO7bnXy[4l{fGmlYXzsfUB4cXSqIHLvdpRmgm:vaXK= M{HW[|I2OTd4M{W0
ACHN M1vzSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvydFQzPS93MDDuUS=> M2TGTFQ5KGh? NX;NPYlHTE2VTx?= Ml3jbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZIhe3mwZYLnbZN1cWOjbHz5JJdqfGhiYn;yeIV7d22rYh?= NIjOTpYzPTF5NkO1OC=>
769-P NXvaXVNIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;v[VI2NzVyIH7N MYO0PEBp NH60TI9FVVOR NUXrSo1HcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJic4nu[ZJocXO2aXPhcIx6KHerdHigZo9zfGW8b33pZi=> MkDiNlUyPzZ|NUS=
Caki-1 M4\DeWNwdG:weTDGc5Ju[XSrb36gRZN{[Xl? M{LSNFUxKG6P NH[4dYs4NTF2IHS= Mlu1SG1UVw>? M4XyWZN2eHC{ZYPz[YQh[2:ub375JIZwem2jdHnvckB{cWewaX\pZ4FvfGy7IHPvcYJqdmWmIIfpeIghf2m2aDDic5J1\XqxbXniJOKh NGjPVnUzPTF5NkO1OC=>
ACHN M4jsN2NwdG:weTDGc5Ju[XSrb36gRZN{[Xl? MXy1NEBvVQ>? MUK3MVE1KGR? NV25XJBwTE2VTx?= Mm\ld5VxeHKnc4Pl[EBkd2yxbomg[o9zdWG2aX;uJJNq\26rZnnjZY51dHliY3;tZolv\WRid3n0bEB4cXSqIHLvdpRmgm:vaXKgxsA> NUCxdolTOjVzN{[zOVQ>
769-P M4XJdGNwdG:weTDGc5Ju[XSrb36gRZN{[Xl? MlznOVAhdk1? M4rqOVcuOTRiZB?= NX;p[mJuTE2VTx?= M{jNUpN2eHC{ZYPz[YQh[2:ub375JIZwem2jdHnvckB{cWewaX\pZ4FvfGy7IHPvcYJqdmWmIIfpeIghf2m2aDDic5J1\XqxbXniJOKh NYjlV2VOOjVzN{[zOVQ>
Caki-1 NXjabm94SXCxcITvd4l{KEG|c3H5 MkjIOVAhdk1? M2CweVQ5KGh? NUfzc3JmTE2VTx?= NXW2[VQzcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= M3H5OlI2OTd4M{W0
ACHN M1vRS2Fxd3C2b4Ppd{BCe3OjeR?= M17RVVUxKG6P MVq0PEBp NGDPOFBFVVOR M1jQPIlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? NVXEboliOjVzN{[zOVQ>
769-P M2PFZWFxd3C2b4Ppd{BCe3OjeR?= NHHuc3Q2OCCwTR?= MWq0PEBp NFXwOVZFVVOR NYXPWY84cW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= NH;WclAzPTF5NkO1OC=>
MDA-MB-231 NYO4UI43VW:{cHjvcI9ocWOjbDDDdpl{fGGuIG\pc4xmfCBqQ2[pJGF{e2G7 MUGxNOKhdk1? Mon4N:Kh\A>? M2LFZWROW09? M3PG[YFtfGW{czDj[YxtKG2xcoDoc4xw\3oEoB?= M4jyd|I1QDFyNEm3
BT-549 M3L6WW1wenCqb3zv[4lk[WxiQ4L5d5RidCCYaX;s[ZQhMEOYKTDBd5NigQ>? NH;hNZoyOMLibl2= M3;F[VPDqGR? MULEUXNQ NYTPOoxy[Wy2ZYLzJINmdGxibX;ydIhwdG:pedMg MXGyOFgyODR7Nx?=
MCF-7  MmfxUY9zeGixbH;nbYNidCCFconzeIFtKF[rb3zleEApS1ZrIFHzd4F6 NXW1[mt3OTEEoH7N M4G0Z|PDqGR? MV3EUXNQ MY\hcJRmenNiY3XscEBud3KyaH;sc4d6yqB? NVnubGt7OjR6MUC0PVc>
MCF-7 M3;scGZ2dmO2aX;uJGF{e2G7 M17uUlUuPTBibl2= M3zublI1KGh? M3zyTWROW09? MmjNdoVlfWOnZDD0bIUhdGW4ZXygc4Yh\XiycnXzd4lwdiCxZjDFVu6yNCCSUjDhcoQhTm:6QUJCpC=> NXziboFvOjR|Nk[0NFc>
CTS NF;vNnBCeG:ydH;zbZMhSXO|YYm= Mo\qNQKBmzRyIH7NxsA> MY[0PEBp MULpcoR2[2W|IHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MnnKNlQzPDR2Mkm=
OCI-AML3  M{XSNmFxd3C2b4Ppd{BCe3OjeR?= MkGwNQKBmzRyIH7NxsA> MlzBOFghcA>? NInFbWRqdmS3Y3XzJIFxd3C2b4Ppd{BqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> M1fiS|I1OjR2NEK5
U937 MnfCRZBweHSxc3nzJGF{e2G7 M{f4NVDjiJN2MDDuUeKh MkLIOFghcA>? M3nRd4lv\HWlZYOgZZBweHSxc3nzJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy M2\IdVI1OjR2NEK5
PC3 MnLCRZBweHSxc3nzJGF{e2G7 NIXxVFkxNTFyMDDuUS=> M{j6N|I1NzR6IHi= NXvZUm9scW6mdXPld{BieG:ydH;zbZMhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NUX4SGRXOjRzNkOyN|A>
PC3-AR NHPMb45CeG:ydH;zbZMhSXO|YYm= NXf4em8{OC1zMECgcm0> MWeyOE81QCCq M17mPYlv\HWlZYOgZZBweHSxc3nzJIlvKGKxdHigeIlu\S1iYX7kJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NHPvcJAzPDF4M{KzNC=>
PC3 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoewNE0yODBibl2= NXrUcpA{OjRxNEigbC=> NFuz[JNqdmS3Y3XzJIFk[3WvdXzheIlwdiCxZjDzeYJIOSCyb4D1cIF1cW:w M4nsNVI1OTZ|MkOw
PC3-AR NHjRUo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmnMNE0yODBibl2= MoHvNlQwPDhiaB?= Mme3bY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dDDpckB1cGViR{LNJJBp[XOn Mmq1NlQyPjN{M{C=
PC3 NULFPVlnTnWwY4Tpc44hSXO|YYm= MUCwMVExOCCwTR?= MV6yOEBp NGixbmR{fXCycnXzd4V{KGW6cILld5Nqd25ib3[gZYN1cX[jdHXkJGFVVSxiQXv0JIFv\CCHcnuxM|IheHKxdHXpci=> Mnf1NlQyPjN{M{C=
PC3-AR MlTYSpVv[3Srb36gRZN{[Xl? MX[wMVExOCCwTR?= M2nwfVI1KGh? M{nzRZN2eHC{ZYPz[ZMh\XiycnXzd4lwdiCxZjDhZ5RqfmG2ZXSgRXRONCCDa4SgZY5lKEW{a{GvNkBxem:2ZXnu M3\0ZVI1OTZ|MkOw
OS-RC-2 NX;4NWM1S2WubDDWbYFjcWyrdImgRZN{[Xl? NHfhfmwxNTFyMECgcm0> NWLyfYpmOjRxNEivO|IhcA>? M2DUOGROW09? MV\k[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZo91cCC2aX3lMUBidmRiZH;z[U1l\XCnbnTlcpQhdWGwbnXy Mk\0NlQyPDR5M{e=
OS-RC-2 M3\JO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHh[YY2OCCwTR?= NVnqbFhWPDhiaB?= M3WxN2ROW09? NH7ySXpqdmS3Y3XzJGczN01iYYLy[ZN1 M174O|I1OTR2N{O3
OS-RC-2 NIXxPWtCeG:ydH;zbZMhSXO|YYm= NWrmeYduPTBibl2= MmLrOFghcA>? M3:xTWROW09? NUSzR4FMcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= MmfWNlQyPDR5M{e=
SK-N-AS M{LlPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVew5qCUQDBibl2= NXvDRXZoPDhiaB?= M2LVdWlEPTB;MkeuOEBvVQ>? MoXWNlQxQTh5OUm=
SK-N-DZ MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1ziflDjiJN6MDDuUS=> NHLIdnA1QCCq M4Tp[WlEPTB;MkGuPUBvVQ>? NGfweHYzPDB7OEe5PS=>
SK-N-SH NFTaSWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYCxUoo1OOLCk{iwJI5O NH;KUmk1QCCq NXmxOJp1UUN3ME23Nk4{KG6P NInieYYzPDB7OEe5PS=>
SK-N-BE MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXjpfpM4OOLCk{iwJI5O MXy0PEBp MVPJR|UxRTd3LkSgcm0> NWrZbnR3OjRyOUi3PVk>
SK-N-AS NYXTSYpnSXCxcITvd4l{KEG|c3H5 NHXkR40x6oDVOECgcm0> MoDuOFghcA>? M3;iZZBwfGWwdHz5JIlv\HWlZXSgZZBweHSxc3nzJIlvKGFiZH;z[U1l\XCnbnTlcpQh\mG|aHnvci=> MlXBNlQxQTh5OUm=
SK-N-DZ NF;MfWtCeG:ydH;zbZMhSXO|YYm= M4TKOFDjiJN6MDDuUS=> MkPFOFghcA>? MV3wc5RmdnSueTDpcoR2[2WmIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JIZie2irb36= NYq3[4VsOjRyOUi3PVk>
SK-N-SH M{DLfWFxd3C2b4Ppd{BCe3OjeR?= NF3qOlgx6oDVNECgcm0> M{\J[lQ5KGh? NF7PVIpxd3SnboTsfUBqdmS3Y3XkJIFxd3C2b4Ppd{BqdiCjIHTvd4Uu\GWyZX7k[Y51KG[jc3jpc44> NIjnUYozPDB7OEe5PS=>
SK-N-BE M3\KTmFxd3C2b4Ppd{BCe3OjeR?= MYew5qCUPDBibl2= MVK0PEBp NGnDS3Nxd3SnboTsfUBqdmS3Y3XkJIFxd3C2b4Ppd{BqdiCjIHTvd4Uu\GWyZX7k[Y51KG[jc3jpc44> M3zaUFI1ODl6N{m5
SK-N-AS MXzGeY5kfGmxbjDBd5NigQ>? NI\QfFQx6oDVOECgcm0> MVi0PEBp M2XEbYlv\HWlZYOgZUBld3OnLXTldIVv\GWwdDDjcIVifmGpZTDv[kBk[XOyYYPlJFMh[W6mIGDBVnA> NEjXPHgzPDB7OEe5PS=>
SK-N-DZ M3TKN2Z2dmO2aX;uJGF{e2G7 NV7VVmV6OOLCk{iwJI5O NFGydlI1QCCq MkHVbY5lfWOnczDhJIRwe2VvZHXw[Y5l\W62IHPs[YF3[WenIH;mJINie3Cjc3WgN{BidmRiUFHSVC=> MUeyOFA6QDd7OR?=
SK-N-SH NWXvVIJMTnWwY4Tpc44hSXO|YYm= MYSw5qCUPDBibl2= MmDhOFghcA>? NWH3TJBqcW6mdXPld{BiKGSxc3Wt[IVx\W6mZX70JINt\WG4YXflJI9nKGOjc4Dhd4UhOyCjbnSgVGFTWA>? MViyOFA6QDd7OR?=
SK-N-BE MVjGeY5kfGmxbjDBd5NigQ>? NHjuR2Yx6oDVNECgcm0> NWrjd2dkPDhiaB?= M133Rolv\HWlZYOgZUBld3OnLXTldIVv\GWwdDDjcIVifmGpZTDv[kBk[XOyYYPlJFMh[W6mIGDBVnA> M1y3N|I1ODl6N{m5
HCC-LM3 M4rUSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWGxMVExODBibl2= NWLaSng{OjRxNEivO|IhcA>? NYDNUXVnTE2VTx?= M{\MeolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZT2gZY5lKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MoTtNlQxQTN7NU[=
HepG2 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVPTT2o1OS1zMECwJI5O NULQWJFkOjRxNEivO|IhcA>? MY\EUXNQ MYTpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWVvIHHu[EBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MlXNNlQxQTN7NU[=
SMMC-7721 MlLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LiO|EuOTByMDDuUS=> NH:wdmMzPC92OD:3NkBp NUPP[FNvTE2VTx?= MYjpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWVvIHHu[EBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NV61ZVlVOjRyOUO5OVY>
HCC-LM3 NEK0cXBCeG:ydH;zbZMhSXO|YYm= M4LhUVUxKG6P NUDCZopZPDhiaB?= MljoSG1UVw>? NWrkfo9ucW6mdXPld{Bk\WyuIHHwc5B1d3OrczDzbYdvcW[rY3HueIx6KGmwIHGgZ4F{eGG|ZT3k[ZBmdmSnboSgcYFvdmW{IHL5JINt\WG4YXflJI9nKGOjc4Dhd4V{KDNuIEigZY5lKDl? M3vCS|I1ODl|OUW2
HepG2 NXv0N3pOSXCxcITvd4l{KEG|c3H5 M4\OSVUxKG6P NFLL[Ho1QCCq MYjEUXNQ MUjpcoR2[2W|IHPlcIwh[XCxcITvd4l{KHOrZ37p[olk[W62bImgbY4h[SClYYPwZZNmNWSncHXu[IVvfCCvYX7u[ZIh[nliY3zlZZZi\2Vib3[gZ4F{eGG|ZYOgN{whQCCjbnSgPS=> Moe4NlQxQTN7NU[=
SMMC-7721 M2PqXmFxd3C2b4Ppd{BCe3OjeR?= NU\VUZZTPTBibl2= MWi0PEBp M37QSmROW09? MX7pcoR2[2W|IHPlcIwh[XCxcITvd4l{KHOrZ37p[olk[W62bImgbY4h[SClYYPwZZNmNWSncHXu[IVvfCCvYX7u[ZIh[nliY3zlZZZi\2Vib3[gZ4F{eGG|ZYOgN{whQCCjbnSgPS=> M4roR|I1ODl|OUW2
HCC-LM3 M1ftRWZ2dmO2aX;uJGF{e2G7 M2fpRlUxNzFyMDDuUS=> NEXPcmkzPCCq NVTzWVV[TE2VTx?= MYnk[YNz\WG|ZYOgeIhmKGyndnXsd{Bw\iCyLWPURXQ{KGGwZDDwMWFsfMLi MoPTNlQxQTN7NU[=
HepG2 Ml:2SpVv[3Srb36gRZN{[Xl? MWi1NE8yODBibl2= MmDmNlQhcA>? NGXScWdFVVOR NWW1ZnNS\GWlcnXhd4V{KHSqZTDs[ZZmdHNib3[gdE1UXEGWMzDhcoQheC2Da4VCpC=> MWeyOFA6Ozl3Nh?=
SMMC-7721 M3[1dmZ2dmO2aX;uJGF{e2G7 NYXDTINxPTBxMUCwJI5O MVKyOEBp NXLQXHQ{TE2VTx?= MVjk[YNz\WG|ZYOgeIhmKGyndnXsd{Bw\iCyLWPURXQ{KGGwZDDwMWFsfMLi MmDwNlQxQTN7NU[=
HCC-LM3 MYfGeY5kfGmxbjDBd5NigQ>? M13PN|UxNzFyMDDuUS=> Ml7NNlQhcA>? MXjEUXNQ NWGzWIdv\G:5boLl[5Vt[XSnczDCZ4wugExiZYjwdoV{e2mxbh?= MnP3NlQxQTN7NU[=
HepG2 NXjDO3VUTnWwY4Tpc44hSXO|YYm= M2TKZ|UxNzFyMDDuUS=> M1jwfVI1KGh? MWrEUXNQ NX7TWZl2\G:5boLl[5Vt[XSnczDCZ4wugExiZYjwdoV{e2mxbh?= NVK0cWI6OjRyOUO5OVY>
SMMC-7721 NV7GOmF{TnWwY4Tpc44hSXO|YYm= Mo[2OVAwOTByIH7N NV\aenhoOjRiaB?= M37XNWROW09? M1;Pe4Rwf26{ZXf1cIF1\XNiQnPsMZhNKGW6cILld5Nqd25? MYSyOFA6Ozl3Nh?=
FaDu MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTrWppVOTBy4pEFcm0> M{PqU|gwOTBxMUKgbC=> NXzWcXBn\Gm|cHzhfYVlKGFic3nncolncWOjboSgZY5lKHC{b3zvcodm\CCJMj;NJIFzemW|dDDheEA5KGGwZDCxNwKBjWhicH;zeEBz\WynYYPl MWSyOFAzPjR6Mh?=
FaDu MWLGeY5kfGmxbjDBd5NigQ>? NHywcXQyODEkgJXuUS=> MXeyM|QwQC9zMjDo NWjBW3BncW6mdXPl[EBxOjGZYX[xM2NqeDIEoHX4dJJme3Orb36= NH7ZNXgzPDB{NkS4Ni=>
PC-3  M1XyRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mne0NE0yOCEQvF2= NXzuUVZPOjRxNEivO|IhcA>? NGH1T|RqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMYRmeGWwZHXueEBu[W6wZYK= Mn\GNlM6QTF{MU[=
LNCaP M3HuXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUSwMVUh|ryP M3i2cVI1NzR6L{eyJIg> M{nL[olvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZT2gZY5lKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= M{DqPVI{QTlzMkG2
RWPE-1  MlrHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnfuNE0zOCEQvF2= NVjUVG11OjRxNEivO|IhcA>? M13zWolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZT2gZY5lKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MVmyN|k6OTJzNh?=
Capan-1 M33Q[WZ2dmO2aX;uJGF{e2G7 M4O5U|I2NzVyL{GwNEBvVQ>? NIXBVFA5NzJ2L{S4JIg> MUnEUXNQ Mmrm[I94dnKnZ4XsZZRm\CCUb36gcXJPSSCjbnSgdJJwfGWrbjDlfJBz\XO|aX;uJIFv\CCmb4fud5Rz\WGvIIPp[45idGmwZx?= NUjCXIZuOjN7MkK4PFY>
L3.6pl NVfsZ2dETnWwY4Tpc44hSXO|YYm= MUCyOU82OC9zMECgcm0> NFfLfII5NzJ2L{S4JIg> MULEUXNQ MXfkc5dvemWpdXzheIVlKFKxbjDtVm5CKGGwZDDwdo91\WmwIHX4dJJme3Orb36gZY5lKGSxd37zeJJm[W1ic3nncoFtcW6p NYDMW2pnOjN7MkK4PFY>
CFPAC-1  NXLxZ2JFTnWwY4Tpc44hSXO|YYm= Mmj6NlUwPTBxMUCwJI5O M1S4WFgwOjRxNEigbC=> NEnwN4lFVVOR MmnS[I94dnKnZ4XsZZRm\CCUb36gcXJPSSCjbnSgdJJwfGWrbjDlfJBz\XO|aX;uJIFv\CCmb4fud5Rz\WGvIIPp[45idGmwZx?= MojDNlM6OjJ6OE[=
Capan-1 NEfjTHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2GyUlI2NzVyL{GwNEBvVQ>? MX60PEBp NYGxSIs5TE2VTx?= MYfy[YR2[2W|IHPlcIwh\3Kxd4ToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NXn4WJp3OjN7MkK4PFY>
L3.6pl MlH2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYOyOU82OC9zMECgcm0> MYm0PEBp MXnEUXNQ M33rfJJm\HWlZYOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> M2nIVFI{QTJ{OEi2
CFPAC-1  NI[5eINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVOxOFZCOjVxNUCvNVAxKG6P NUnyWlYzPDhiaB?= NHHySVRFVVOR NVPOT3hnemWmdXPld{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M{fTOFI{QTJ{OEi2
Capan-1 MnzvRZBweHSxc3nzJGF{e2G7 M1XmOVI2NzVyL{GwNEBvVQ>? M1vZeFQ5KGh? M1nWeWROW09? NGrOSoVqdmS3Y3XzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NIq5d4QzOzl{Mki4Oi=>
L3.6pl NWrGeWtySXCxcITvd4l{KEG|c3H5 MX2yOU82OC9zMECgcm0> MkLkOFghcA>? NF:zeJRFVVOR NHLMOIpqdmS3Y3XzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MX2yN|kzOjh6Nh?=
CFPAC-1  MoDaRZBweHSxc3nzJGF{e2G7 M4PYdFI2NzVyL{GwNEBvVQ>? MVW0PEBp NXTDdXN7TE2VTx?= NHTKOnRqdmS3Y3XzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NWjRcnc5OjN7MkK4PFY>
HN22 NFryN45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjlfItwOC1{MDDuUS=> NVLZNVRZOjRxNEigbC=> M1XrfGROW09? MVHpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMUBl\XCnbnTlcpQhdWGwbnXy M2r5O|I{QDd5MkO1
HSC4  MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYHEOnBiOC1{MDDuUS=> NE\HXIUzPC92ODDo Mn3ISG1UVw>? MnWxbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliaX6gZo91cCC2aX3lMUBidmRiZH;z[U0h\GWyZX7k[Y51KG2jbn7ldi=> M{Dr[FI{QDd5MkO1
HN22 MknwRZBweHSxc3nzJGF{e2G7 Mmn2NE0zOCCwTR?= MYm0PEBp MXnEUXNQ NXH1SJJwcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= NUTTU|k4OjN6N{eyN|U>
HSC4  NXi1NFVxSXCxcITvd4l{KEG|c3H5 MmntNE0zOCCwTR?= NELMRZo1QCCq M{e5cGROW09? MmXYbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? NHnGZoIzOzh5N{KzOS=>
HN22 NH7UNZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEL6eYcxNTJyIH7N MVu0PEBp M3fGXGROW09? MXfpcoR2[2W|IFexJJBp[XOnIHPlcIwh[3mlbHWgZZJz\XO2wrC= NULrfFNoOjN6N{eyN|U>
HSC4  MofXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{XIWVAuOjBibl2= NX21S|lSPDhiaB?= M4D6XWROW09? M{W3Nolv\HWlZYOgS|EheGijc3WgZ4VtdCCleXPs[UBienKnc4VCpC=> MVqyN|g4PzJ|NR?=
HN22 NHvZTGhHfW6ldHnvckBCe3OjeR?= MWGwMVIxKG6P NHjl[3c1QCCq M4n2b2ROW09? MVnzeZBxemW|c3XzJHNxOSCneIDy[ZN{cW:wwrC= MX2yN|g4PzJ|NR?=
HSC4  NXLpXokyTnWwY4Tpc44hSXO|YYm= MVGwMVIxKG6P NGG3PGw1QCCq MmTySG1UVw>? MX\zeZBxemW|c3XzJHNxOSCneIDy[ZN{cW:wwrC= NFfhNY4zOzh5N{KzOS=>
Cal62 NVvuOnRmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTN|INMxJFQhdk1? NFTQSVczOzh{NEC2OC=>
Hth7 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYjlTFhsUUN3ME2xOUDDuSB{IH7N NYj5elRTOjN6MkSwOlQ>
Hth83 NH7sNYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M12wWGlEPTB;M{SgxtEhPSCwTR?= M4OyOlI{QDJ2ME[0
C643 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPyZWdKSzVyPUexJOKyKDFyIH7N NH:2RZMzOzh{NEC2OC=>
SW1736 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmrWTWM2OD1|NTFCtUA5KG6P NXGyXohCOjN6MkSwOlQ>
T241 NVL3bWo2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PoXmlEPTB;NkWgxtEhPyCwTR?= MVuyN|gzPDB4NB?=
T351 MkfvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWDWcWJGUUN3ME21NEDDuSBzMDDuUS=> MYiyN|gzPDB4NB?=
BHP2-7 M3\zN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIm3c45KSzVyPUO3JOKyKDZibl2= NUP5OZV7OjN6MkSwOlQ>
T238 MmXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnP1TWM2OD1zLEWwNEDDuSB{MECgcm0> M1;qZ|I{QDJ2ME[0
HCT8 MlLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1HofVczKGh? NFWyVZZFVVOR NVPzflM6UUN3ME2xNk466oDLwsJihKkyNjlibl2= NUjwXm0{OjN{OUmzPFg>
H630 M{P4cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXPDXJE2PzJiaB?= NFXQfFlFVVOR MYjJR|UxRTF{LkVihKnDueLCiUOuNUBvVQ>? MXGyN|I6QTN6OB?=
cH630 5-FU-res MonBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVG3NkBp NW\vdVgzTE2VTx?= MYjJR|UxRTF3LkZihKnDueLCiUGuNkBvVQ>? NF\TZoQzOzJ7OUO4PC=>
HCT116 NXnvNIxCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFfnSHU4OiCq NIf4UZdFVVOR NUPWd4oyUUN3ME2xNE446oDLwsJihKkzNjJibl2= M{TUSFI{Ojl7M{i4
HCT116 p53−/− MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlLwO|IhcA>? M1P3S2ROW09? MmKwTWM2OD16LkdihKnDueLCiUGuO{BvVQ>? M2\jU|I{Ojl7M{i4
dHCT116 p21−/− Mom2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHTlWJk4OiCq NYC4ZmhbTE2VTx?= MV3JR|UxRTVwOfMAjeKy6oDLMT6zJI5O M1v5Z|I{Ojl7M{i4
HT29 NGPkNYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\CU2k4OiCq NInTVWZFVVOR NHPmenBKSzVyPUG2MlPjiIoEsfMAjVIvOyCwTR?= M2nJbVI{Ojl7M{i4
LoVo MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPMO|IhcA>? MYjEUXNQ NF2zdIhKSzVyPUWuNgKBkcLz4pEJNE43KG6P MWGyN|I6QTN6OB?=
RKO M1jUVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW[3NkBp MkezSG1UVw>? NGTOOmRKSzVyPUeuPgKBkcLz4pEJNk4zKG6P M17aSVI{Ojl7M{i4
SW480 NYixbIp4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnHQO|IhcA>? NGnWT4FFVVOR MofPTWM2OD1zNz615qCKyrIkgJmwMlghdk1? NXPtUYMxOjN{OUmzPFg>
eSW620 MoHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV23NkBp NVPMbIhbTE2VTx?= NUexU|R[UUN3ME25MlHjiIoEsfMAjVIvOSCwTR?= MlnQNlMzQTl|OEi=

... Click to View More Cell Line Experimental Data

In vivo In lung cancer and mesothelioma animal models, LBH589 markedly decreases tumor growth by 62%. LBH589 is equally effective in immunocompetent and severe combined immunodeficien-cymice, suggesting that the inhibition of tumor growth by LBH589 is not due to direct immunologic effects. Daily LBH589, given i.p. at 20 mg/kg for 5 days per week, leading to an average decrease in growth of 70%. Compared with the corresponding control tumors, LBH589 leads to a 53% decrease for H526-derived tumors, an 81% decrease for BK-T-derived tumors, a 76% decrease for RG-1- derived tumors, and a 70% decrease for H69-derived tumors. In contrast to the lack of tumor regression notes in NSCLC and Meso-derived xenografted tumors that are treated under identical conditions and doses, LBH589 results in dramatic tumor regression in SCLC-derived tumors and RG-1-derived tumor. [2]

Protocol

Cell Research:[1]
+ Expand
  • Cell lines: MOLT-4 cell lines and Reh (pre-B cells)
  • Concentrations: 50 nM
  • Incubation Time: 48 hours
  • Method: Untreated and LBH589-treated cells [human Ph- acute lymphoblastic leukemia MOLT-4 (T cells) and Reh (pre-B cells)] are stained with annexin V and propidium iodide using annexin V-FITC apoptosis detection kit I. The percentage of apoptotic and nonviable cells is determined by flow cytometry. At least 5 × 104 cells are collected with a CyAn ADP Violet cytometer. Percentage apoptosis is calculated considering all the annexin V-positive plus the annexin V/PI-positive cells; percentage loss of cell viability is calculated considering all the annexin V-positive plus the PI-positive and the annexinV/PI-positive cells.
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: Severe combined immunodeficiency (SCID) mice with M30 (107 cells) or A549 (5 × 106 cells), H69 (2.5 × 106 cells), BK-T (6.5 × 106), H526 (10 × 106), and RG1 (10 × 106) cells
  • Formulation: Dextrose 5% in water
  • Dosages: 10 mg/kg, 20 mg/kg
  • Administration: Administered via i.p. injection
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 69 mg/mL (197.46 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+48% PEG 300+2% Tween 80+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 349.43
Formula

C21H23N3O2

CAS No. 404950-80-7
Storage powder
in solvent
Synonyms NVP-LBH589

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02032810 Active not recruiting Melanoma|Skin Cancer H. Lee Moffitt Cancer Center and Research Institute|Novartis January 7 2014 Phase 1
NCT03256045 Recruiting Recurrent Plasma Cell Myeloma|Refractory Plasma Cell Myeloma University of Washington|National Cancer Institute (NCI) May 31 2018 Phase 2
NCT01169636 Completed Hodgkin''s Lymphoma M.D. Anderson Cancer Center|Novartis January 31 2011 Phase 1|Phase 2
NCT02676323 Recruiting Acute Myeloid Leukemia|Myelodysplastic Syndrome St. Jude Children''s Research Hospital May 3 2016 Phase 1
NCT02717455 Recruiting Glioma Pediatric Brain Tumor Consortium June 28 2016 Phase 1
NCT01301807 Active not recruiting Non-Secretory Plasma Cell Myeloma|Plasmacytosis|Recurrent Plasma Cell Myeloma|Refractory Plasma Cell Myeloma M.D. Anderson Cancer Center|National Cancer Institute (NCI) July 28 2011 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    How to reconstitute the compound for in vivo mice study?

  • Answer:

    We recommend the vehicle is 2 % DMSO, 2 % Tween 80, 48%PEG300, 48% water. The compound is first dissolved in DMSO, then add Tween, PEG300, water in sequence.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products5

Tags: buy Panobinostat (LBH589) | Panobinostat (LBH589) supplier | purchase Panobinostat (LBH589) | Panobinostat (LBH589) cost | Panobinostat (LBH589) manufacturer | order Panobinostat (LBH589) | Panobinostat (LBH589) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID